Flexion Therapeutics, Inc. (FLXN) financial statements (2022 and earlier)

Company profile

Business Address 10 MALL ROAD
BURLINGTON, MA 01803
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

9/30/2021
TTM
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including: 175,300136,700258,800423,900210,329118,604
Cash and cash equivalents 107,70482,25387,229127,78930,91562,944
Short-term investments 67,57654,407171,555264,589174,68848,303
Other undisclosed cash, cash equivalents, and short-term investments 20401631,5224,7257,357
Receivables 30,27137,35313,8381,38860595
Inventory, net of allowances, customer advances and progress billings 15,39416,5297,6371,799  
Inventory 15,39416,5297,6371,799  
Prepaid expense 4,3465,0724,7172,3591,085135
Other undisclosed current assets 5002150(31,456)(2,625)(6,732)
Total current assets: 225,811195,675285,042397,990209,394112,103
Noncurrent Assets
Operating lease, right-of-use asset 6,5778,223
Property, plant and equipment 19,53813,66210,71011,18911,6647,442
Long-term investments and receivables    31,5384,7257,357
Long-term investments    31,5384,7257,357
Restricted cash and investments    60048080
Other noncurrent assets      156
Total noncurrent assets: 26,11521,88510,71043,32716,86915,036
TOTAL ASSETS: 251,926217,560295,752441,317226,262127,139
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities 26,93634,86826,65020,6058,4068,059
Accounts payable 6,92815,25812,3406,2222,1613,692
Accrued liabilities 20,00819,61014,31014,3836,2454,367
Deferred revenue 10,000 
Debt 16,8061,3519,9679,9679,134 
Other undisclosed current liabilities 1,526     
Total current liabilities: 55,26836,21936,61730,57217,5408,059
Noncurrent Liabilities
Long-term debt and lease obligation 50,23747,7853,64012,93621,39915,002
Long-term debt, excluding current maturities 44,11440,1763,64012,93621,39915,002
Operating lease, liability 6,1237,609
Liabilities, other than long-term debt 29525153742829191
Other liabilities 29525153742829191
Other undisclosed noncurrent liabilities 162,786153,413144,879137,107  
Total noncurrent liabilities: 213,318201,449149,056150,47121,69015,093
Total liabilities: 268,586237,668185,673181,04339,23023,152
Stockholders' equity
Stockholders' equity attributable to parent (16,660)(20,108)110,079260,274187,032103,986
Common stock 493838383222
Additional paid in capital 765,607648,391628,944609,810398,757243,854
Accumulated other comprehensive income (loss) (11)62(77)(407)(71)(97)
Accumulated deficit (782,305)(668,599)(518,826)(349,167)(211,686)(139,792)
Total stockholders' equity: (16,660)(20,108)110,079260,274187,032103,986
TOTAL LIABILITIES AND EQUITY: 251,926217,560295,752441,317226,262127,139

Income statement (P&L) ($ in thousands)

9/30/2021
TTM
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Revenues 85,55272,95722,524355  
Revenue, net355  
Cost of revenue
(Cost of Goods and Services Sold)
 (19,249)(9,960)(7,336)(4)  
Gross profit: 66,30362,99715,188351  
Operating expenses (159,322)(199,268)(174,390)(130,032)(69,780)(46,063)
Operating loss: (93,019)(136,271)(159,202)(129,681)(69,780)(46,063)
Nonoperating expense (20,192)(13,502)(10,457)(7,800)(2,114)(252)
Investment income, nonoperating 8763,2124,5673,7181,5211,246
Other nonoperating income (expense) (1,041)352688(250)(1,887)(928)
Interest and debt expense (20,027)(352)(15,712)(11,268)(1,747)(571)
Loss from continuing operations before equity method investments, income taxes: (133,238)(150,125)(185,371)(148,749)(73,641)(46,886)
Other undisclosed income from continuing operations before income taxes 20,027     
Loss from continuing operations before income taxes: (113,211)(150,125)(185,371)(148,749)(73,641)(46,886)
Income tax expense (495)     
Loss before gain (loss) on sale of properties: (113,706)(150,125)(185,371)(148,749)(73,641)(46,886)
Other undisclosed net income  35215,712   
Net loss: (113,706)(149,773)(169,659)(148,749)(73,641)(46,886)
Other undisclosed net income attributable to parent    11,2681,747571
Net loss available to common stockholders, diluted: (113,706)(149,773)(169,659)(137,481)(71,894)(46,315)

Comprehensive Income ($ in thousands)

9/30/2021
TTM
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Net loss: (113,706)(149,773)(169,659)(148,749)(73,641)(46,886)
Other comprehensive income (loss)     26(91)
Comprehensive loss: (113,706)(149,773)(169,659)(148,749)(73,615)(46,978)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent (73)13933010,9321,747571
Comprehensive loss, net of tax, attributable to parent: (113,779)(149,634)(169,329)(137,817)(71,868)(46,407)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: